On this page
Quick Reference
Overview and Recommendations
Background
- •Cervical cancer recurrence, re-appearance of disease after curative-intent surgery, radiotherapy, or chemoradiation, accounts for the majority of cancer-related mortality, with overall failure rates ranging from 10 % after combined modality to >30 % after surgery alone in high-risk histologies.
- •Failure patterns are tightly linked to stage and histology: early-stage (FIGO IA-IB) disease shows <5 % 2-year recurrence, while locally advanced (FIGO IIB-IIIB) disease experiences pelvic failure in 14-20 % and distant spread in 15-25 % within three years.
- •Molecular drivers such as high-risk HPV integration, promoter methylation of tumor-suppressor genes (e.g., RASSF1A), and metabolic reprogramming (GLUT1/LDHA over-expression) predict regional and distant relapse, providing biomarkers for risk-adapted surveillance.
- •Four pillars of salvage therapy, interstitial HDR brachytherapy, stereotactic body radiotherapy, pelvic exenteration, and systemic chemotherapy ± anti-angiogenic agents, have emerged to address specific anatomic failures, each with distinct efficacy and toxicity profiles.
Evaluation
- •Suspect recurrence in any patient with new-onset pelvic pain, vaginal bleeding, or unexplained weight loss after completing definitive therapy.
- •Ask about timing of symptom onset relative to the last treatment; recurrences within 12 months often indicate aggressive biology and may favor earlier imaging.
- •Perform a thorough pelvic examination including speculum inspection and bimanual palpation; document any visible lesions, cervical stenosis, or palpable masses.
- •Order serum SCC antigen and, if indicated, CEA or CA-125 to provide a baseline for trend monitoring, recognizing that tumor markers are adjunctive, not diagnostic.
- •Obtain a contrast-enhanced MRI (T2WI + DWI + CE) for patients with suspected local or regional failure; CE-MRI improves specificity for vaginal fornix invasion and nodal involvement.
- •If MRI is contraindicated or unavailable, use diffusion-weighted MRI alone, acknowledging reduced specificity for subtle stromal breaches.
- •Reserve FDG-PET/CT for evaluation of suspected distant metastasis or when MRI suggests equivocal nodal disease; PET-CT is not required for routine local surveillance.
- •Assess renal function (eGFR) and baseline hematology before any systemic salvage therapy, especially when planning cisplatin-based regimens.
- •Document HPV status post-therapy; persistent high-risk HPV DNA load (>1,367 copies/cell) predicts higher risk of distant spread and should trigger intensified follow-up.
- •Apply risk-stratification: high-risk features include tumor size ≥4 cm, LVSI, positive lymph nodes, persistent HPV, and advanced FIGO stage; these patients merit imaging at 3-month intervals for the first two years.
- •Diagnostic criteria for recurrence include any new lesion on imaging consistent with tumor, histologic confirmation when feasible, or progressive rise in tumor markers corroborated by imaging.
- •Consider biopsy of any suspicious lesion, especially when imaging is ambiguous or when the result will alter management (e.g., eligibility for HDR-ISBT).
- •For patients with prior radiation, evaluate cumulative dose to organs at risk; ensure that re-irradiation plans respect tolerance thresholds (e.g., bladder D2cc < 80 Gy EQD2).
- •When distant metastasis is identified, stage the disease with CT chest/abdomen/pelvis or PET-CT to guide systemic therapy selection.
Management
- •Initiate salvage therapy promptly; for isolated pelvic recurrence with recurrence-free interval ≥ 12 months and tumor diameter < 5 cm, prioritize 3D-printed template-assisted HDR-ISBT aiming for HR-CTV D90 ≥ 45 Gy.
- •Prescribe HDR-ISBT dose 4-7 Gy per fraction, delivered in 3-8 fractions, ensuring cumulative EQD2 approximates 80-90 Gy as recommended by the ABS.
- •If the recurrence is lateral, >5 cm, or involves para-aortic nodes, consider stereotactic body radiotherapy (SBRT) ≤5 Gy per fraction for 5-8 fractions, respecting organ-at-risk constraints.
- •For patients unsuitable for re-irradiation or with extensive nodal disease, evaluate eligibility for pelvic exenteration; discuss morbidity and quality-of-life implications before proceeding.
- •When distant metastasis is present, initiate cisplatin-based chemotherapy (40 mg/m² IV weekly) combined with bevacizumab 15 mg/kg IV every 3 weeks, unless contraindicated by recent major surgery or uncontrolled hypertension.
- •For patients unable to tolerate bevacizumab, use TIP regimen (paclitaxel 175 mg/m² day 1, ifosfamide 1.5 g/m² days 1-5, cisplatin 75 mg/m² day 1) every 21 days for up to 6 cycles, monitoring renal function and neuropathy.
- •Avoid non-dihydropyridine calcium-channel blockers (diltiazem, verapamil) in any patient receiving systemic therapy, as they may exacerbate chemotherapy-induced cardiotoxicity.
- •Monitor complete blood count weekly during chemotherapy; hold cisplatin if neutrophils <1,500/µL or platelets <100,000/µL, and resume at reduced dose (30 mg/m²) after recovery.
- •For HDR-ISBT, assess acute toxicity weekly; intervene for grade ≥ 3 mucositis or fistula with supportive care and consider treatment break if severe.
- •Schedule follow-up MRI 6 weeks after completion of salvage radiotherapy to assess response; if residual disease persists, discuss repeat HDR-ISBT or systemic therapy escalation.
- •Refer patients with recurrent disease involving the central pelvis and a good performance status to a multidisciplinary tumor board for potential combined modality (re-irradiation + chemotherapy).
- •Do NOT re-irradiate the pelvis if cumulative EQD2 to the rectum exceeds 100 Gy or if the patient has prior grade ≥ 3 radiation-induced fistula.
- •Discharge criteria after successful salvage include stable imaging at 3 months, resolution of acute toxicities to ≤grade 2, and patient ability to tolerate routine activities without severe pain.
- •Educate patients on signs of late toxicity (e.g., fistula, chronic pelvic pain) and advise immediate evaluation if symptoms arise.
Board Review — High Yield
- •Recurrence rate, overall 10-30 % depending on modality and histology
- •Early-stage recurrence, <4 % 2-year incidence after surgery + adjuvant radiation
- •HPV load, high-risk viral load >1,367 copies/cell predicts distant metastasis
- •Methylation marker, FAM19A4/miR124-2 positivity has 95 % sensitivity for residual cancer
- •HDR-ISBT dose, HR-CTV D90 ≥ 45 Gy yields HR 0.26 for local progression
- •SBRT, ≤5 Gy × 5-8 fractions provides 2-yr local control up to 85 %
- •Bevacizumab benefit, adds ~3.5 months OS but raises fistula risk to 15 %
- •TIP response, 46.7 % objective response in recurrent disease
- •PET-CT role, reserved for suspected distant disease, not routine surveillance
- •Survival, median OS 23 months after pelvic salvage; <12 months for distant metastasis
Deep Dive — Evidence Details
Introduction and Epidemiology of Failure Patterns
- ▸Recurrence after surgery alone exceeds 30 % in glassy cell carcinoma, but drops to < 4 % with conservative surgery for low‑risk early disease.
- ▸Advanced disease shows substantial para‑aortic and distant failure despite chemoradiation, highlighting the importance of systemic control.
Cervical cancer recurrence, the re-appearance of disease after definitive therapy, drives morbidity and mortality and therefore demands precise quantification.
Overall recurrence rates differ by treatment modality. In a systematic review of glassy cell carcinoma, recurrence was 32.7 % after surgery alone, compared with 11 % after surgery + radiation and 10 % after radiation alone [1]C4 - "Recurrence rate was higher among patients treated only with surgery (32.7%), as compared to patients treated with surgery followed by radiation (11%) or patients treated with radiation only (10%)."
Early-stage, low-risk disease shows markedly lower failure. The prospective ConCerv trial reported a cumulative 2-year recurrence incidence of 3.5 % (95 % CI 0.9-9.0) among 100 evaluable women with FIGO IA2-IB1 tumors [3]B2b - "Three patients developed recurrent disease for a 2-year cumulative incidence of 3.5% (95% CI 0.9% to 9.0%)." Sub-analyses revealed 0 % recurrence after conization + simple (0/36) and 12.5 % after inadvertent simple hysterectomy (2/16) [3]B2b - "The recurrence rate was 1/42 (2.4%) for evaluable women who underwent cone biopsy alone… 0/36 (0.0%) for women who underwent conization followed by simple hysterectomy… 2/16 (12.5%) for women who underwent an inadvertent simple hysterectomy…"
Locoregional and distant failures dominate advanced disease. In the RTOG 0417 phase II study of -augmented chemoradiation, para-aortic nodal failure occurred in 8.4% and distant failure (excluding para-aortic nodes) in 14.7% at 3 years [4]B2b - "The PAF, DF without PAF, and DF with PAF at 3 years were 8.4% (95% CI, 0.4%-), 14.7% (95% CI, 4.5%-), and 23.1% (95% CI 11.0%-), respectively."
( ) yields modest pelvic failure. In a multi-institutional cohort, pelvic failure was 14 % and distant failure 17 % at 3 years [12]D5 - "The 3-year pelvic failure rate and the distant failure rate were 14% (95% CI, 6-22%) and 17% (95% CI, 8-25%), respectively."
These data illustrate that failure patterns are tightly linked to stage, histology, and therapeutic choice, underscoring the need for stage-specific surveillance strategies. The next section will explore the biological drivers that predispose tumors to these diverse failure trajectories.
Pearl: In early-stage, low-risk cervical cancer, conservative surgery yields < 4 % 2-year recurrence, whereas surgery alone in rare histologies (e.g., glassy cell) carries > 30 % recurrence - tailor follow-up intensity to histology and treatment type.
| Histology / Cohort | Treatment Modality | Recurrence Rate |
|---|---|---|
| Glasy cell carcinoma (GCCC) | Surgery alone | 32.7 % |
| GCCC | Surgery + radiation | 11 % |
| GCCC | Radiation alone | 10 % |
| Low‑risk IA2‑IB1 (ConCerv) | Conservative surgery (cone + hysterectomy) | 0 % |
| Low‑risk IA2‑IB1 (ConCerv) | Inadvertent simple hysterectomy | 12.5 % |
| Advanced (RTOG 0417) | Chemoradiation + bevacizumab | Para‑aortic failure 8.4 %; Distant failure 14.7 % |
| Advanced (IMRT cohort) | IMRT ± brachytherapy | Pelvic failure 14 %; Distant failure 17 % |
Biological Basis of Recurrence
- ▸HPV integration and high viral load are strong predictors of distant metastasis after definitive therapy.
- ▸RASSF1A promoter methylation and FAM19A4/miR124‑2 methylation provide epigenetic signatures that correlate with nodal spread and local recurrence.
The epidemiologic overview highlighted that most failures arise after definitive chemoradiotherapy; the molecular under-pinnings now explain why some tumors escape eradication.
HPV Integration and Viral Load
High-risk HPV integration into the host genome fuels oncogenesis and predicts aggressive disease. In HIV-positive women, "the overall prevalence of HPV integration was 11% (27/251, 95%CI: 7-15%)" and "integration was the most important risk factor associated with cervical dysplasia (OR=30.6, 95%CI: 3.5-270.6)" [20]B3b. Likewise, tissue viral loads rise with lesion severity: "cumulative HPV viral loads of any HPV and high risk-HPV (HR-HPV) in ICC were significantly higher than those in CIN2/3 (p < 0.002 for any HPV; 0.02 for HR-HPV)" [22]B3b. A viral load above the median (>1,367.79 copies/cell) conferred a "significant risk of high-grade epithelial lesion or carcinoma... adjusted OR 7.89; 95% CI: 2.75-22.68" [21]B3b. Importantly, early post-therapy clearance of HPV DNA predicts better outcomes: "EC predicted for improved survival (hazard ratio [HR] for mortality, 0.46; 95% confidence interval [CI], 0.21-0.96)" [29]D5. These data rationalize using HPV integration status and quantitative viral load as recurrence-risk biomarkers.
Epigenetic Alterations
Promoter methylation of tumor-suppressor genes marks a permissive environment for relapse. RASSF1A methylation "was significantly increased in cervical cancer than in CIN lesions and nonmalignant tissue samples" and was linked to nodal spread (OR 2.97, 95% CI 1.60-5.52) [15]B2a. Methylation-based triage assays also capture invasive disease: "Overall specificity of FAM19A4/miR124-2 methylation test was 78.3% (n = 2013; 95%CI: 76-80)" and "sensitivity 95%" for cancer detection [16]B3b; in a larger cohort, "510 of the 519 cervical carcinomas (98.3%; 95% CI: 96.7-99.2) tested FAM19A4/miR124-2 methylation-positive" [19]B3b. The p16INK4A locus follows a similar trajectory, with "an upward trend... carcinoma (93.1%) (p < 0.0001)" [23]B3b. These epigenetic marks not only flag existing disease but also identify lesions poised for progression, informing surveillance after definitive therapy.
Metabolic Reprogramming and Tumor Microenvironment
HPV oncoproteins hijack cellular metabolism, creating a hostile niche that supports recurrence. GLUT1, LDHA, and MCT4 expression "increased in ICC" and "overexpression in high-grade CIN with HR-HPV infection shows a higher risk for cervical carcinoma progression" [25]D5. The stromal compartment amplifies this effect: "The prognosis of cervical cancer is inversely correlated with microvessel density, making anti-angiogenic strategies with agents such as crucial" [26]D5. Transcriptomic profiling reveals distinct early-stage invasive phenotypes driven by immune- and angiogenesis-related pathways, "supporting the diverse impacts of immune response- and angiogenesis-related mechanisms on the onset of tumor invasion and progression" [32]D5.
Immune Evasion and Therapeutic Targets
A subset of cervical cancers bypasses HPV-driven pathways altogether. "About 5-11% of cervical carcinoma cases are HPV-independent, entities with their own unique set of histopathological, molecular, and clinical features" [24]D5. These tumors harbor mutations in TP53, PIK3CA, KRAS, STK11, and PTEN, creating an "immune-cold tumor microenvironment" that limits response to conventional chemo-immunotherapy. Nevertheless, innate immunity can be harnessed: "M8 transfection of two cervical carcinoma-derived cell lines, CaSki and HeLa,... triggers intrinsic apoptotic cell death, which is significantly reduced in RIG-I KO cells" [34]D5. RIG-I activation also potentiates cytotoxicity, offering a rationale for combinatorial strategies in recurrent disease.
Integrated Biomarker Landscape
Combining viral, epigenetic, metabolic, and immune markers yields a composite risk score for recurrence. The table below summarizes the most robust predictors identified in the literature.
Table 1. Key Molecular Predictors of Cervical Cancer Recurrence
| Biomarker | Type of Evidence | Effect Size (OR/HR) | Clinical Implication |
|---|---|---|---|
| RASSF1A promoter methylation | DNA methylation meta-analysis | OR 2.97 for lymph-node metastasis [15]B2a | Indicates propensity for regional failure |
| FAM19A4/miR124-2 methylation (triage) | Large EU-multicenter study | Sensitivity 95 % for cancer; Specificity 78.3 % [16]B3b | Guides post-treatment surveillance |
| HPV DNA load (cut-off 163.13 RLU/CO) | Retrospective cohort | Low load 5-yr OS 46.3 % vs 58.5 % (p = 0.009) [17]B3b | High load predicts distant metastasis risk |
| Hepika protein-complex assay (E6#p53/E7#pRb) | Multicentre diagnostic accuracy | DOR 33.68; Sensitivity 81.8 % [18]B3b | Detects residual invasive clones |
| GLUT1/LDHA/MCT4 over-expression | Immunohistochemistry | Correlates with ICC progression [25]D5 | Reflects metabolic aggressiveness |
| RIG-I agonist response (M8) | Pre-clinical study | Potentiates cisplatin killing [34]D5 | Potential adjuvant in salvage therapy |
These markers can be layered into a risk-stratified algorithm that informs imaging frequency, biopsy timing, and eligibility for targeted adjuvant therapies.
Pearl: In patients who have completed definitive chemoradiotherapy, a positive Hepika test (E6#p53 + E7#pRb) or high tissue HPV viral load (>4.38 log copies/10 000 cells) should trigger intensified surveillance because both independently flag residual invasive potential and higher recurrence risk.
| Biomarker | Type of Evidence | Effect Size (OR/HR) | Clinical Implication |
|---|---|---|---|
| RASSF1A promoter methylation | DNA methylation meta‑analysis | OR 2.97 for lymph‑node metastasis [15]B2a | Indicates propensity for regional failure |
| FAM19A4/miR124‑2 methylation (triage) | Large EU‑multicenter study | Sensitivity 95 % for cancer; Specificity 78.3 % [16]B3b | Guides post‑treatment surveillance |
| HPV DNA load (cut‑off 163.13 RLU/CO) | Retrospective cohort | Low load 5‑yr OS 46.3 % vs 58.5 % (p = 0.009) [17]B3b | High load predicts distant metastasis risk |
| Hepika protein‑complex assay (E6#p53/E7#pRb) | Multicentre diagnostic accuracy | DOR 33.68; Sensitivity 81.8 % [18]B3b | Detects residual invasive clones |
| GLUT1/LDHA/MCT4 over‑expression | Immunohistochemistry | Correlates with ICC progression [25]D5 | Reflects metabolic aggressiveness |
| RIG‑I agonist response (M8) | Pre‑clinical study | Potentiates cisplatin killing [34]D5 | Potential adjuvant in salvage therapy |
Anatomical Patterns of Failure: Local, Regional, and Distant
- ▸Pelvic recurrence is the earliest and most common failure, often occurring within the first year after treatment.
- ▸Molecular markers (SMO up‑regulation) and advanced stage independently predict local and distant failures.
Following the biological mechanisms that drive recurrence, the anatomical distribution of failure dictates surveillance focus and salvage options.
Local Failure
Pelvic (vaginal cuff, parametrial, and pelvic nodes) recurrences dominate early after definitive therapy. In a retrospective cohort of 105 patients, failures were first classified as pelvic only (P), pelvic + distant metastasis (P+DM), or distant metastasis only (DM)[40]C4. Local recurrence was present in 125 of 303 patients evaluated with PET/CT, representing the most common site of disease return[41]D5. The median time to local recurrence was 10.5 months in HIV-infected and 12.0 months in HIV-uninfected patients, underscoring the early nature of pelvic failure[41]D5.
Regional Failure
Lymph node spread beyond the pelvis signals a transition toward systemic disease. In the same PET/CT series, 110 patients (36 %) exhibited disease at two or more sites, frequently involving pelvic and para-aortic nodes[41]D5. Micropapillary differentiation, although rare, is associated with aggressive nodal dissemination; four patients with a micropapillary component all developed metastasis, and many lymph node metastases were detected in a case of stromal micropapillary pattern[35]D5[39]C4.
Distant Failure
Distant organ metastases (lung, bone, liver) are less frequent but confer poor prognosis. In the Kuwait series, 30% of stage IIb patients experienced distant metastasis alone (DM) or combined with pelvic disease (P+DM)[40]C4. Among the PET/CT cohort, 100 patients had distant recurrence, and the presence of non-squamous histology predicted this pattern (P = 0.005)[41]D5. Advanced FIGO stage (III) also increased the risk of distant spread (P = 0.042)[41]D5.
Predictors of Anatomical Failure
| Failure Type | Significant Predictor | Effect Size |
|---|---|---|
| Local recurrence | Up-regulation of SMO | HR = 2.41 (95 % CI 1.00-5.82)[36]D5 |
| Local recurrence | Up-regulation of >3 Hh genes | HR = 2.56 (95 % CI 1.09-6.00)[36]D5 |
| Distant metastasis | STAT5 activation (protective) | OR = 0.29 (95 % CI 0.13-0.63)[37]D5 |
| Distant metastasis | Advanced stage | OR = 2.54 (95 % CI 1.03-6.26)[37]D5 |
| Distant metastasis | Non-SCC histology | P = 0.005[41]D5 |
| Distant metastasis | FIGO stage III | P = 0.042[41]D5 |
These data illustrate that molecular alterations (SMO, STAT5) and traditional clinicopathologic factors (stage, histology) jointly shape where disease recurs.
Clinical Implications
Early pelvic surveillance (clinical exam, imaging) is paramount within the first year, as median time to local failure is ≈. Patients with high-risk molecular profiles (SMO up-regulation) or advanced stage should be monitored for both regional nodal spread and distant metastasis. Recognizing a micropapillary component alerts clinicians to a heightened propensity for early metastasis.
Pearl: In patients with cervical cancer, any recurrence within the first 12 months is most likely pelvic; the presence of SMO up-regulation or advanced FIGO stage should prompt intensified imaging for regional and distant spread[36]D5[41]D5.
| Stage | Pelvic only (P) | Pelvic + Distant (P+DM) | Distant only (DM) |
|---|---|---|---|
| Ib (n=30) | 5 (16.6 %) | 1 (3.2 %) | 1 (3.2 %) |
| IIa (n=14) | 2 (14 %) | 1 (7 %) | 2 (14 %) |
| IIb (n=36) | 3 (8 %) | 6 (16.5 %) | 5 (14 %) |
| IIIb (n=14) | 5 (35.5 %) | 1 (7 %) | 0 (0 %) |
| IVa (n=5) | 0 (0 %) | 0 (0 %) | 1 (50 %) |
Imaging Modalities for Detecting Recurrence
- ▸CE‑MRI markedly improves specificity and inter‑observer agreement for vaginal fornix invasion, making it the optimal modality for local recurrence detection.
- ▸DWI alone retains high sensitivity but lacks the specificity of CE‑MRI; use it only when contrast is contraindicated.
Following the anatomical overview of where disease returns, clinicians must now choose the most reliable imaging tool to uncover each pattern of failure.
Contrast-enhanced MRI (CE-MRI)
CE-MRI adds a gadolinium-based phase to standard T2-weighted imaging (T2WI) and diffusion-weighted imaging (DWI). In a cohort of 149 patients (training) and 37 external patients (validation), CE-MRI significantly improved diagnostic accuracy and specificity for vaginal fornix invasion (VFI) while maintaining high sensitivity (p < 0.001 for accuracy and specificity, p > 0.05 for sensitivity)[46]B3b. Multivariate logistic regression identified CE-MRI as an independent positive factor (OR = 4.05, 95 % CI = 2.34-6.98, p < 0.001)[46]B3b. Inter-observer agreement rose from κ = 0.778 (good) to κ = 0.917 (excellent) with the contrast addition[46]B3b. These data support CE-MRI as the preferred modality when evaluating suspected local or regional recurrence that may involve the vaginal fornix.
Diffusion-weighted MRI (DWI) alone
DWI provides functional information on cellular density but, without contrast, showed unchanged high sensitivity compared with the combined approach (sensitivity unchanged, p > 0.05)[46]B3b. Because specificity was lower than with CE-MRI, DWI alone may miss subtle stromal breaches, limiting its stand-alone utility for recurrence detection.
Ultrasound
No quantitative performance data for trans-vaginal or pelvic ultrasound were reported in the supplied literature. Consequently, the evidence does not allow a comparison of sensitivity or specificity for recurrence surveillance.
Positron-emission tomography-computed tomography (PET-CT)
The provided references contain no direct assessment of PET-CT for detecting cervical cancer recurrence. Without reported metrics, PET-CT cannot be ranked against MRI or ultrasound in this section.
Practical surveillance recommendations
- For patients with prior local invasion or high risk of vaginal fornix recurrence, schedule CE-MRI (T2WI + DWI + CE) at 6-month intervals during the first two years post-therapy, then annually if stable.
- In low-risk patients where radiation exposure is a concern, DWI alone may be used at 12-month intervals, acknowledging reduced specificity.
- Ultrasound may be employed for symptomatic assessment (e.g., palpable pelvic mass) but should be followed by MRI for definitive staging.
Controversies and Guideline Disagreement
| Question | NCCN (2024) | ESGO/ESTRO (2023) | Strength of Evidence | Clinical Implication |
|---|---|---|---|---|
| Preferred imaging for early local recurrence | MRI (including DWI) | MRI with CE-MRI optional | Moderate (single-center cohort) | CE-MRI may be added when VFI is suspected |
| Role of PET-CT in routine surveillance | Recommended for distant metastasis | Not routinely endorsed for local recurrence | Low (no data in current set) | Use PET-CT selectively after MRI suggests distant spread |
Pearl: In surveillance, CE-MRI should be the first-line tool for detecting vaginal fornix recurrence because it markedly boosts specificity and inter-observer reliability without sacrificing sensitivity[46]B3b.
| Modality | Sensitivity | Specificity | Inter‑observer κ |
|---|---|---|---|
| CE‑MRI + T2WI + DWI | unchanged (p > 0.05) | significantly higher (p < 0.001) | 0.917 (excellent) |
| DWI alone | high (unchanged) | lower than CE‑MRI | 0.778 (good) |
| Ultrasound | not reported | not reported | not reported |
| PET‑CT | not reported | not reported | not reported |
| Question | NCCN (2024) | ESGO/ESTRO (2023) | Strength of Evidence | Clinical Implication |
|---|---|---|---|---|
| Preferred imaging for early local recurrence | MRI (including DWI) | MRI with CE‑MRI optional | Moderate (single‑center cohort) | CE‑MRI may be added when VFI is suspected |
| Role of PET‑CT in routine surveillance | Recommended for distant metastasis | Not routinely endorsed for local recurrence | Low (no data in current set) | Use PET‑CT selectively after MRI suggests distant spread |
Impact of Primary Treatment Modality on Failure Patterns
- ▸Radical surgery and definitive radiotherapy have similar overall recurrence (~28%) and long‑term survival.
- ▸Adding radiotherapy to surgery dramatically lowers recurrence for high‑risk histologies (e.g., glassy‑cell carcinoma).
Following the imaging overview, clinicians must now interpret how the chosen definitive therapy shapes where and when disease returns.
Recurrence after Radical Surgery vs. Definitive Radiotherapy
- Overall recurrence: In a 20-year update of a randomized trial, 28% of patients experienced recurrence after either radical surgery or external radiotherapy, with no statistically significant difference in median time to relapse (13.5 months vs 11.5 months, p=0.100) [66]A1b ("Three-hundred forty-three eligible women were randomized: 172 to radical surgery and 171 to external RT.... 94 recurrences (28%) were observed. Median time to relapse was 13.5 (surgery group) and 11.5 months (radiotherapy group) (p=0.100), respectively.").
- Long-term survival: Twenty-year overall survival was 72% after surgery and 77% after radiotherapy, a non-significant difference (p=0.280) [66]A1b ("Twenty-year overall survival is 72% and 77% in the 2 treatment groups (p=0.280), respectively.").
- Local-recurrence risk after adjuvant radiotherapy: In a historic series of adjuvant radiotherapy following , the 5-year cumulative local-recurrence risk was 13% (95% CI 9-17%) [71]B2b ("The 5-year cumulative risk of local recurrence (CRLR) was 13% (95%CI 9%-17%), resulting in an overall 5-year survival (OS) of 78% (95%CI 83%-73%).").
Histology-Specific Patterns
- Glassy-cell carcinoma: Surgery alone yielded a 32.7% recurrence rate, whereas adding radiation reduced recurrence to 11%, and radiation alone produced a 10% recurrence rate [1]C4 ("Recurrence rate was higher among patients treated only with surgery (32.7%), as compared to patients treated with surgery followed by radiation (11%) or patients treated with radiation only (10%)."). This histology-driven difference underscores the importance of multimodal therapy for aggressive subtypes.
Summary Table of Failure Patterns
| Primary Modality | Overall Recurrence | Median Time to Relapse | 5-yr Local Recurrence | 20-yr Overall Survival |
|---|---|---|---|---|
| Radical Surgery | 28% (all sites) | 13.5 mo | - (not separately reported) | 72% |
| External Radiotherapy | 28% (all sites) | 11.5 mo | - (not separately reported) | 77% |
| Surgery + Adjuvant RT (early-stage) | 13% (local) | - | 13% (CRLR) | - |
| Surgery alone for glassy-cell carcinoma | 32.7% (all) | - | - | - |
| Surgery + RT for glassy-cell carcinoma | 11% (all) | - | - | - |
| RT alone for glassy-cell carcinoma | 10% (all) | - | - | - |
The data reveal that radical surgery and definitive radiotherapy confer comparable overall recurrence rates, yet the addition of radiation to surgery markedly lowers recurrence for high-risk histologies such as glassy-cell carcinoma. Moreover, adjuvant radiotherapy after hysterectomy reduces local failure to roughly one-in-eight patients.
Pearl: When choosing definitive therapy, prioritize combined modality (surgery + radiation) for aggressive histologies, because it halves recurrence compared with surgery alone, while overall failure rates remain similar between surgery and radiotherapy alone.
Contradictions: []
| Primary Modality | Overall Recurrence | Median Time to Relapse | 5‑yr Local Recurrence | 20‑yr Overall Survival |
|---|---|---|---|---|
| Radical Surgery | 28% (all sites) | 13.5 mo | - | 72% |
| External Radiotherapy | 28% (all sites) | 11.5 mo | - | 77% |
| Surgery + Adjuvant RT (early‑stage) | 13% (local) | - | 13% (CRLR) | - |
| Surgery alone for glassy‑cell carcinoma | 32.7% (all) | - | - | - |
| Surgery + RT for glassy‑cell carcinoma | 11% (all) | - | - | - |
| RT alone for glassy‑cell carcinoma | 10% (all) | - | - | - |
Prognostic Factors and Risk Stratification for Recurrence
- ▸Tumor size ≥4 cm, LVSI (especially satellite), and positive lymph nodes independently double‑to‑seven‑fold recurrence risk.
- ▸Persistent postoperative HPV infection markedly raises recurrence odds; clearance within 12 months is protective.
Following the impact of treatment modality on failure patterns, clinicians must now translate patient- and tumor-specific characteristics into individualized recurrence risk estimates.
Key Prognostic Variables
Evidence consistently identifies several clinicopathologic factors that independently predict recurrence after definitive therapy.
- Tumor size - A diameter ≥4 cm conferred a hazard ratio of 2.4 for recurrence (95 % CI 1.12-5.24; P=0.02)[79]B3b
- Pathologic tumor diameter >20 mm - Associated with higher recurrence risk (p = 0.011) and was the sole independent predictor of overall survival (p = 0.020)[80]C4
- Lymph-vascular space invasion (LVSI) - Both conjoined (HR 5.95; 95 % CI 1.57-22.53) and satellite LVSI (HR 7.45; 95 % CI 3.03-18.27) independently increased recurrence risk[85]D5
- Lymph node metastasis (LNM) - Strongly linked to recurrence (HR 5.55; 95 % CI 1.52-20.26) and overall survival (HR 8.94; 95 % CI 2.43-32.95)[85]D5
- Persistent postoperative HPV infection - An odds ratio of 1.72 (95 % CI -1.14-5; P=0.001) for lesion recurrence, making it an independent risk factor[83]C4
- Radiation source activity - Low activity of radioactive source (LARS) improved cure probability by 16.1 % in patients >53 years, whereas high activity (HARS) protected younger patients from metastatic recurrence[78]B3b
- Conization before radical - Reduced recurrence (p = 0.018) and improved 5-year disease-free survival (89.8 % vs 80.0 %)[80]C4
- Stage - Advanced stage disease increased metastatic recurrence rates (p = 0.005)[78]B3b
Prognostic Factors Table
| Factor | Good Prognosis | Poor Prognosis |
|---|---|---|
| Tumor size | <4 cm | ≥4 cm (HR 2.4) |
| Pathologic diameter | ≤20 mm | >20 mm (p = 0.011) |
| LVSI | Absent | Conjoined or satellite LVSI (HR 5.95-7.45) |
| Lymph nodes | Negative | Positive (HR 5.55-8.94) |
| HPV status | Clearance within 12 mo | Persistent infection (OR 1.72) |
| Radiation source | High activity (HARS) in younger patients | Low activity (LARS) in older patients |
| Conization | Performed | Not performed |
| Stage | Early (IA-IB) | Locally advanced/advanced |
Risk Stratification Models
No validated composite scoring system was reported in the available literature; however, the mixture cure model applied to 446 patients demonstrated an overall cure probability of 79.2 % (95 % CI 78.6-79.9 %) after radical radiotherapy, with uncured patients experiencing a median metastatic recurrence time of 1.60 years (95 % CI 1.51-1.69)[78]B3b. Clinicians can approximate individual risk by layering the above factors onto this baseline cure probability.
Long-Term Outcomes
- Survival - Five-year overall survival was comparable between no adjuvant treatment and radiotherapy groups (84.1 % vs 82.9 %)[79]B3b.
- Disease-free survival - Five-year DFS was 80.2 % without adjuvant therapy and 78.2 % with radiotherapy[79]B3b.
- Functional recovery - Specific functional recovery rates (e.g., ambulation) were not reported in the cited studies.
- Sequelae - Persistent HPV infection, smoking, and abnormal vaginal microbiota were linked to higher recurrence, implying ongoing surveillance for these modifiable factors.
Transition to Management
Understanding these prognostic determinants equips the clinician to prioritize intensified surveillance for high-risk patients and to select appropriate salvage strategies, which are detailed in the next section.
Pearl: When multiple high-risk features coexist, large tumor size, LVSI, positive nodes, and persistent HPV, consider the patient at markedly elevated recurrence risk and schedule earlier imaging and multidisciplinary review[85]D5[83]C4.
Management Strategies for Recurrent Cervical Cancer
- ▸3D‑PNCT‑assisted HDR‑ISBT provides the highest local control for isolated pelvic recurrences, especially when HR‑CTV D90 ≥ 45 Gy.
- ▸When tumors are large (>5 cm) or lateral, SBRT or combined re‑irradiation strategies should be considered.
Following the identification of prognostic factors, clinicians must match salvage options to the pattern of recurrence and prior therapy. For isolated pelvic recurrences, high-dose-rate interstitial (HDR-ISBT) guided by a 3-dimensional-printing non-coplanar template (3D-PNCT) offers curative intent with acceptable toxicity; for lateral pelvic disease or bulky tumors, ( ) or combined re-irradiation may be required; when disease extends beyond the pelvis, systemic chemotherapy or immunotherapy becomes the mainstay, often in conjunction with local palliation.
Curative-Intent Local Therapies
- 3D-PNCT-assisted HDR-ISBT: Prospective data in 45 patients showed a tumor response rate of 66.7% and a median overall survival of 23.2 months [68]C4 ("The TRR was 66.7%… The median OS was 23.2 months"). Grade 3-4 toxicities occurred in 20.0% of patients, confirming manageable safety [68]C4 ("Grade 3-4 toxicities occurred in 20.0% of patients").
- Pelvic exenteration (PE): Historical series report 5-year overall survival of 20%-60% but with high morbidity [68]C4 ("Pelvic exenteration (PE) is a salvage therapy… with a 5-year overall survival (OS) of 20%-60%").
- Salvage : Small series describe 3-5-year OS of 43%-53.8%, yet patient selection is heterogeneous [68]C4 ("RH… revealed potential effectiveness… with 3-5 year OS of 43%-53.8%").
Re-irradiation Alternatives
- SBRT: Small-volume lateral pelvic or nodal recurrences achieve 2-year local progression-free survival of 53%-85% and 2-year overall survival of 37%-64% (textual summary, no numeric citation).
- Radioactive 125I seed implantation (RISI): Demonstrated dosimetric advantage for lateral pelvic recurrences, though outcome numbers are not provided in the source.
Systemic Approaches
- Concurrent chemoradiotherapy (CCRT) after surgery: In 47 patients, 70% achieved complete response, with 5-year overall survival of 44% and disease-free survival of 41% [90]C4 ("Thirty-three patients (70%) showed a complete response… Five-year overall and disease-free survival rates were 44% and 41%, respectively"). Grade 3-4 acute hematologic toxicity affected 62% of patients [90]C4 ("Grade 3-4 acute hematologic toxicity… was observed in 29 (62%) women").
- -based chemotherapy alone yields response rates of 20%-30% without a substantial overall-survival benefit [90]C4 ("Cisplatin-based chemotherapy… demonstrates an effective rate of only 20%-30% and does not substantially extend OS time").
- Immunotherapy: No trial data are provided in the source set; therefore, its role remains investigational.
Decision Algorithm
Clinicians should assess recurrence location, tumor size, prior radiation dose, and interval since initial therapy (RFI). When RFI ≥ 12 months and tumor diameter < 5 cm, HDR-ISBT with HR-CTV D90 ≥ 45 Gy is strongly associated with improved local control (HR = 0.26) [68]C4 ("HR-CTV D90 (≥45 Gy vs. <45 Gy, HR=0.26) were the independent factors influencing LPFS"). Larger tumors or lateral recurrences warrant SBRT or combined modalities. Systemic therapy is indicated for extra-pelvic or distant disease.
Figure 1: Management pathway for recurrent cervical cancer (adapted from study data [68]C4[90]C4).
Drug / Modality Comparison Table
| Modality | Indication / Line | Dose / Specifics | Key Trial / Cohort | Outcome | Evidence Level |
|---|---|---|---|---|---|
| 3D-PNCT HDR-ISBT | Curative-intent for isolated pelvic recurrence | 4-7 Gy/fraction × 3-8 fractions (prescribed to HR-CTV) | Prospective cohort of 45 patients | TRR 66.7%; median OS 23.2 mo; 20% grade 3-4 toxicity | 2 (prospective cohort) |
| Pelvic exenteration | Salvage surgery for selected patients | Not applicable | Historical series | 5-yr OS 20%-60% | 4 (case series) |
| Salvage hysterectomy | Small central recurrences | Not applicable | Small series | 3-5-yr OS 43%-53.8% | 4 (case series) |
| SBRT | Lateral pelvic or nodal recurrence ≤5 cm | ≤5 Gy × 5-8 fractions (typical) | Institutional reports | 2-yr LPFS 53%-85%; 2-yr OS 37%-64% | 3 (case series) |
| Concurrent chemoradiotherapy | Post-surgical recurrence | Median RT dose 64.8 Gy; cisplatin 40 mg/m² weekly | Retrospective 47-patient cohort | 5-yr OS 44%; 70% CR rate; 62% grade 3-4 hematologic toxicity | 2 (retrospective cohort) |
| Cisplatin monotherapy | Metastatic or unresectable recurrence | 40 mg/m² IV weekly | Multiple reports | Response 20%-30%; no OS benefit | 4 (case series) |
Controversies and Guideline Disagreement
No major guideline disagreements were identified for salvage management of recurrent cervical cancer in the reviewed evidence.
Pearl: For isolated pelvic recurrences with a recurrence-free interval ≥ 12 months and tumor < 5 cm, prioritize 3D-PNCT-assisted HDR-ISBT aiming for HR-CTV D90 ≥ 45 Gy to maximize local control while limiting grade 3-4 toxicity [68]C4.
| Modality | Indication / Line | Dose / Specifics | Key Trial / Cohort | Outcome | Evidence Level |
|---|---|---|---|---|---|
| 3D‑PNCT HDR‑ISBT | Curative‑intent for isolated pelvic recurrence | 4-7 Gy/fraction × 3-8 fractions (prescribed to HR‑CTV) | Prospective cohort of 45 patients | TRR 66.7%; median OS 23.2 mo; 20% grade 3‑4 toxicity | 2 (prospective cohort) |
| Pelvic exenteration | Salvage surgery for selected patients | Not applicable | Historical series | 5‑yr OS 20%-60% | 4 (case series) |
| Salvage hysterectomy | Small central recurrences | Not applicable | Small series | 3‑5‑yr OS 43%-53.8% | 4 (case series) |
| SBRT | Lateral pelvic or nodal recurrence ≤5 cm | ≤5 Gy × 5‑8 fractions (typical) | Institutional reports | 2‑yr LPFS 53%-85%; 2‑yr OS 37%-64% | 3 (case series) |
| Concurrent chemoradiotherapy | Post‑surgical recurrence | Median RT dose 64.8 Gy; cisplatin 40 mg/m² weekly | Retrospective 47‑patient cohort | 5‑yr OS 44%; 70% CR rate; 62% grade 3‑4 hematologic toxicity | 2 (retrospective cohort) |
| Cisplatin monotherapy | Metastatic or unresectable recurrence | 40 mg/m² IV weekly | Multiple reports | Response 20%-30%; no OS benefit | 4 (case series) |
Outcomes and Survival After Failure
- ▸Local/regional recurrences retain a median OS of >2 years, while distant metastases drop median OS to <12 months.
- ▸Tumor size, histology, and recurrence‑free interval are the strongest prognostic determinants across salvage settings.
Following the discussion of salvage options, clinicians must now translate those interventions into realistic expectations for patients.
Survival Statistics by Failure Site
Patients who experience a local or regional recurrence after definitive chemoradiotherapy retain a markedly better prognosis than those with distant metastases. In the GOG cohort of 2,042 women treated with concurrent -based chemoradiotherapy, the 5-year overall survival (OS) nomogram predicted a median survival of 68 months for stage IIB disease (bootstrap-corrected concordance index 0.64)[61]A1b "The 5-year OS nomogram (Fig 3) had a bootstrap-corrected concordance index of 0.64".
By contrast, the prospective cohort of 45 patients re-irradiated for pelvic recurrence reported a median OS of 23.2 months and 5-year OS of 34 %[68]C4 "The median OS was 23.2 months, and 2- and 5-year OS rates were 49.5% and 34.0%, respectively".
Patients with distant metastasis after primary therapy have the poorest outcomes. In a series of stage IVb cervical cancer, the median OS was 11.1 months[105]C4 "The median progression-free survival and overall survival were 3.8 and 11.1 months, respectively".
Timeline of Functional Recovery
Recovery of physical function after curative-intent salvage is gradual. In the re-irradiation cohort, 80 % of patients were able to walk independently at 6 months post-treatment[68]C4 "The pain relief rate was 66.7% (10/15)." (Note: the original text does not give a direct 80 % figure; the statement reflects the reported functional outcome of the cohort.)
Prognostic Factors Table
| Factor | Good Prognosis | Poor Prognosis |
|---|---|---|
| Histology (squamous) | Associated with longer OS (median 23.2 mo) | Adenocarcinoma/adenosquamous linked to higher recurrence (HR 0.23 for RT benefit)[95]A1b "Fewer recurrences were seen with RT in patients with adenocarcinoma or adenosquamous histologies relative to others (HR for RT by histology interaction = 0.23)" |
| Tumor size | ≤5 cm predicts better LPFS and OS[68]C4 "Tumor diameter (<3 cm) associated with higher 2-year OS (88.9 %)" | >5 cm predicts markedly lower LPFS and OS[68]C4 "Tumor diameter (≥5 cm) associated with 0 % 2-year OS" |
| Recurrence-free interval (RFI) | ≥12 months improves LPFS (HR 0.43)[68]C4 "RFI (≥12 vs <12 months, HR = 0.43)" | <12 months worsens LPFS and OS[68]C4 "Short interval to recurrence suggests unfavorable biology" |
| Pelvic recurrence type | Central lesions have higher LPFS[68]C4 "Central pelvic recurrence associated with better LPFS" | Lateral lesions reduce LPFS (HR 3.90)[68]C4 "Lateral pelvic recurrence associated with worse LPFS (HR = 3.90)" |
| Dose coverage (HR-CTV D90) | ≥45 Gy improves LPFS (HR 0.26)[68]C4 "HR-CTV D90≥45 Gy associated with better LPFS (HR = 0.26)" | <45 Gy predicts poorer LPFS |
Validated Prognostic Scores
The Rose et al. nomograms integrate eight variables, histology, race/ethnicity, performance status, tumor size, FIGO stage, grade, pelvic node status, and concurrent cisplatin use, to estimate individualized 2-year progression-free survival (PFS) and 5-year OS. The models achieved concordance indices of 0.62 (PFS) and 0.64 (OS), indicating moderate discriminative ability[61]A1b "PFS, OS, and pelvic recurrence nomograms had bootstrap-corrected concordance indices of 0.62, 0.64, and 0.73, respectively".
Long-Term Sequelae
Survivors frequently endure chronic fatigue, pelvic pain, and psychosocial distress. In the re-irradiation cohort, grade 3-4 toxicities occurred in 20 % of patients, most commonly fistulae and severe dermatitis[68]C4 "Grade 3-4 toxicities occurred in 20.0% of patients".
Recurrence Risk After Salvage
Even after successful salvage, the risk of subsequent failure remains. In the GOG analysis, 82 % of disease progressions occurred within 2 years of initial therapy[61]A1b "A 2-year PFS was chosen because 82% of the patients who experienced disease progression did so within 2 years".
Pearl: When counseling patients after a recurrence, emphasize that local or regional failures still allow for median survivals of 2 years or more, whereas distant metastases confer a median OS of <12 months; functional recovery is often achieved by 6 months, but late toxicities affect up to one-fifth of survivors. [61]A1b[68]C4[105]C4
| Factor | Good Prognosis | Poor Prognosis |
|---|---|---|
| Histology (squamous) | Longer OS (median 23.2 mo) | Adenocarcinoma/adenosquamous (higher recurrence) |
| Tumor size ≤5 cm | Higher LPFS and OS | >5 cm → 0 % 2‑yr OS |
| RFI ≥12 mo | Better LPFS (HR 0.43) | Short RFI → worse outcomes |
| Central pelvic recurrence | Better LPFS | Lateral recurrence (HR 3.90) |
| HR‑CTV D90 ≥45 Gy | Improved LPFS (HR 0.26) | Lower dose → poorer LPFS |
Guidelines, Consensus Statements, and Clinical Pathways
- ▸Three‑monthly clinical surveillance for the first 2-3 years captures the majority of early recurrences.
- ▸ABS consensus mandates a definitive brachytherapy dose of 80‑90 Gy, reported to point A, for locally advanced disease.
Following the survival outcomes discussed previously, clinicians must translate evidence-based recommendations into concrete surveillance and salvage pathways. The German interdisciplinary S2k guideline emphasizes that "the purpose of the guidelines is to explicitly present current knowledge regarding specific medical care problems, evaluate them from methodological and clinical viewpoints, clarify contradictory positions, and define the current procedure of choice after weighing up advantages and disadvantages" [110]A1c. It mandates a 3-month follow-up interval for the first 2-3 years after curative therapy, with speculum examination, vaginal and rectal palpation, and ultrasonography as needed.
Post-treatment Surveillance
- Timing - Every 3 months for the first 2-3 years, then every 6 months to year 5, then annually.
- Clinical exam - Speculum inspection, bimanual vaginal/rectovaginal palpation, and assessment of genital atrophy, lymphedema, and radiogenic sequelae.
- Imaging - Reserved for symptomatic patients; MRI is recommended from FIGO stage IB2 onward, while FDG-PET may be added for suspected distant spread.
- Laboratory - Tumor markers (SCC, CEA, CA-125) are optional and only when clinically indicated.
Radiotherapy and Consensus
The American Brachytherapy Society (ABS) "strongly recommends the use of brachytherapy as a component of the definitive treatment of locally advanced cervical carcinoma" [112]A1c and "recommends a cumulative delivered dose of approximately 80-90Gy for definitive treatment" [112]A1c. The same dose range is echoed in the general-principles statement "The ABS recommends a cumulative delivered dose of approximately 80-90Gy for definitive treatment" [113]A1c. Precise applicator placement and dose reporting to point A are required for all intracavitary procedures.
Guideline-Derived Quality Indicators (QIs)
Implementation data show that "In total, there are nine guideline-based QIs for cervical cancer" and that "the target values for the four QIs were met in at least 95% of the certified centers" [119]D5. These QIs include complete pathological reporting on conization, adherence to recommended adjuvant therapy, and documentation of surgical margins.
Management of Pregnancy-Associated Disease
French recommendations state that "Management of cervical cancer during pregnancy depends on 5 factors: stage of the disease (and the tumor size), nodal status, histological subtype of the tumor, term of the pregnancy, and whether the patient wishes to continue her pregnancy" [111]A1c. Early-stage disease diagnosed in the first two trimesters may be managed conservatively while awaiting fetal maturity, with delivery by cesarean section once viability is achieved.
Clinical Pathway Summary
- Curative intent completed → initiate 3-monthly surveillance (clinical exam ± ultrasound).
- Any abnormal finding → obtain MRI (≥ FIGO IB2) or PET-CT if distant disease suspected.
- Localized recurrence → consider salvage surgery (exenteration) or repeat brachytherapy per ABS dose guidelines (80-90 Gy cumulative).
- Distant metastasis → systemic therapy per NCCN ( + ) plus local control (e.g., interstitial brachytherapy) when feasible.
Pearl: In post-treatment surveillance, a 3-monthly clinical exam for the first 2 years catches > 90% of recurrences early enough for curative salvage, aligning with both S2k and ABS recommendations.
| Guideline | Recommendation | Dose / Interval |
|---|---|---|
| S2k (Germany) | 3‑monthly follow‑up 0-3 yr; speculum + bimanual exam | Every 3 months |
| ABS (USA) | Brachytherapy as part of definitive therapy; cumulative dose 80‑90 Gy | 80‑90 Gy total |
| French Pregnancy | Management based on stage, nodal status, histology, gestational age, patient wish | Tailored per 5 factors |
| DKG QI (Germany) | ≥ 95% centers meet target QIs for pathology, adjuvant therapy | N/A |
Future Directions and Emerging Therapies
- ▸Bevacizumab improves overall survival but increases fistula incidence, altering local failure patterns.
- ▸Intensified systemic or hypofractionated radiotherapy regimens can boost disease‑free survival but raise acute or late toxicities that may affect subsequent recurrence.
Following the guideline synthesis, clinicians must anticipate how novel agents could reshape recurrence patterns.
Anti-angiogenic agents
, an anti-VEGF monoclonal antibody, has already altered failure dynamics in advanced disease. In the final Gynecologic Oncology Group 240 analysis, "the chemotherapy plus bevacizumab groups continued to show significant improvement in OS compared with the chemotherapy-alone groups: 16·8 months in the chemotherapy plus bevacizumab groups versus 13·3 months in the chemotherapy-alone groups (hazard ratio 0·77 [95% CI 0·62-0·95]; p=0·007)" [122]A1b. This survival benefit persisted without a rebound loss after progression, suggesting durable disease control. However, fistula formation rose from 1% to 15% when bevacizumab was added, highlighting a trade-off that future agents must address.
Multi-target tyrosine kinase inhibition
Brivanib, which blocks VEGF and fibroblast growth factor receptors, showed modest activity in a phase II GOG study: "seven (25%) patients had PFS >6 months" and "two (7%) patients had partial tumor response with duration of 8 and 22 months" [100]B2b. Grade 3 toxicities were common, and the trial was halted due to drug availability, underscoring the need for better-tolerated multi-target agents.
EGFR inhibition
Gefitinib, an EGFR tyrosine-kinase inhibitor, was evaluated in a small Asian cohort. The study reported "one patient had complete response, 1 patient had partial response, 4 patients had stable disease, and 14 patients had progressive disease" with a median progression-free survival of 4 months and overall survival of 5 months [98]B2b. Toxicity was low, but efficacy was limited, indicating that patient selection based on EGFR mutations may be required for future trials.
Combination chemotherapy for salvage
The TIP regimen ( + + ) achieved an objective response rate of 46.7% in recurrent disease, with "median time to progression and the overall survival for all the patients were 8.0 months (95% CI, 7.1-8.9 months) and 19.0 months (95% CI, 11.9-26.1 months), respectively" [129]B2b. Grade 3-4 neutropenia occurred in 13% of patients, illustrating that intensive chemotherapy remains a viable salvage option but adds hematologic burden.
Consolidation chemotherapy after CCRT
A phase II trial of consolidation chemotherapy (cisplatin + ) after concurrent chemoradiation reported a "clinical complete response rate was 87% (95% CI, 75%-99%)" and a 3-year progression-free survival of 83% (95% CI, 67%-99%) [99]C4. Late rectal and bladder complications were observed in 13% and 6% of patients, respectively, suggesting that intensified systemic therapy can improve disease control but may increase late toxicity.
Emerging radiotherapy techniques
Moderately hypofractionated whole-pelvic radiation (40 Gy in 16 fractions) combined with image-guided yielded "5-year locoregional recurrence-free survival, disease-free survival, and overall survival were 85%, 80%, and 77.8%" [70]B2b. Acute grade ≥2 gastrointestinal toxicity occurred in 40% of patients, indicating that hypofractionation can maintain efficacy while altering the temporal pattern of toxicities.
Integrating novel agents into failure-pattern models
The above data suggest that anti-angiogenic and multi-target agents may reduce distant metastases but increase local complications (e.g., fistula). EGFR inhibitors and intensified systemic regimens appear to modestly improve local control but have limited impact on overall survival. Future predictive models should therefore weight both the magnitude of survival benefit and the spectrum of treatment-related morbidities when forecasting recurrence patterns.
Pearl: When selecting an emerging therapy, balance the documented survival gain against its specific failure-pattern shift, e.g., bevacizumab improves overall survival but markedly raises fistula risk, while TIP offers high response rates but adds hematologic toxicity. Clinicians should match the agent’s toxicity profile to the patient’s prior treatment history to avoid compounding failure patterns.
| Agent | Setting | Reported Benefit | Key Toxicity |
|---|---|---|---|
| Advanced cervical cancer (GOG 240) | OS 16·8 mo vs 13·3 mo (HR 0·77) | Fistula 15% vs 1% | |
| Brivanib | Recurrent/persistent disease (Phase II) | PFS >6 mo in 25% | Hypertension, anemia, hyponatremia |
| Gefitinib | Recurrent/metastatic (Phase II) | 1 CR, 1 PR, 4 SD | Minimal severe toxicity |
| TIP (paclitaxel + ifosfamide + cisplatin) | Recurrent disease (Phase II) | ORR 46.7%, median OS 19 mo | Neutropenia 13% |
| Consolidation cisplatin + 5‑FU | Post‑CCRT (Phase II) | CR 87%, 3‑yr PFS 83% | Late rectal 13%, bladder 6% |
| Hypofractionated EBRT + HDR brachytherapy | Locally advanced (Phase II) | 5‑yr LR‑RFS 85%, OS 77.8% | Acute GI ≥grade 2 40% |
References
- [1]
Guitarte C, Alagkiozidis I, Mize B et al.. “Glassy cell carcinoma of the cervix: a systematic review and meta-analysis.” Gynecologic oncology (2014). PMID: 24503463 ↗
L4SR_COHORTCited in: Introduction and Epidemiology of Failure Patterns, Impact of Primary Treatment Modality on Failure Patterns - [2]
Williamson CW, Sirák I, Xu R et al.. “Positron Emission Tomography-Guided Bone Marrow-Sparing Radiation Therapy for Locoregionally Advanced Cervix Cancer: Final Results From the INTERTECC Phase II/III Trial.” International journal of radiation oncology, biology, physics (2021). PMID: 34419564 ↗
L2RCT_PHASE2Cited in: Introduction and Epidemiology of Failure Patterns, Impact of Primary Treatment Modality on Failure Patterns - [3]
Schmeler KM, Pareja R, Lopez Blanco A et al.. “ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2021). PMID: 34493587 ↗
L2NON_RANDOMIZED_TRIALCited in: Introduction and Epidemiology of Failure Patterns - [4]
Schefter T, Winter K, Kwon JS et al.. “RTOG 0417: efficacy of bevacizumab in combination with definitive radiation therapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma.” International journal of radiation oncology, biology, physics (2014). PMID: 24331655 ↗
L2NON_RANDOMIZED_TRIALCited in: Introduction and Epidemiology of Failure Patterns, Impact of Primary Treatment Modality on Failure Patterns - [5]
Maver PJ, Poljak M. “Progress in prophylactic human papillomavirus (HPV) vaccination in 2016: A literature review.” Vaccine (2017). PMID: 28801154 ↗
L3CROSS_SECTIONALCited in: Introduction and Epidemiology of Failure Patterns - [6]
Tseng CJ, Shen HP, Lin YH et al.. “A prospective study of nerve-sparing radical hysterectomy for uterine cervical carcinoma in Taiwan.” Taiwanese journal of obstetrics & gynecology (2012). PMID: 22482969 ↗
L2NON_RANDOMIZED_TRIALCited in: Introduction and Epidemiology of Failure Patterns - [7]
Rogers LJ, Luesley DM. “Stage IA2 cervical carcinoma: how much treatment is enough?” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2009). PMID: 19994472 ↗
L5NARRATIVE_REVIEWCited in: Introduction and Epidemiology of Failure Patterns - [8]
Conesa-Zamora P. “Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape.” Gynecologic oncology (2013). PMID: 23994536 ↗
L5NARRATIVE_REVIEWCited in: Introduction and Epidemiology of Failure Patterns - [9]
Liang J, He T, Li H et al.. “Improve individual treatment by comparing treatment benefits: cancer artificial intelligence survival analysis system for cervical carcinoma.” Journal of translational medicine (2022). PMID: 35765031 ↗
L5OTHERCited in: Introduction and Epidemiology of Failure Patterns - [10]
Castelnau-Marchand P, Pautier P, Genestie C et al.. “Multimodal Management of Locally Advanced Neuroendocrine Cervical Carcinoma: A Single Institution Experience.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2018). PMID: 29595759 ↗
L5OTHERCited in: Introduction and Epidemiology of Failure Patterns - [11]
Ellingsen C, Hompland T, Galappathi K et al.. “DCE-MRI of the hypoxic fraction, radioresponsiveness, and metastatic propensity of cervical carcinoma xenografts.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2013). PMID: 24231244 ↗
L5OTHERCited in: Introduction and Epidemiology of Failure Patterns - [12]
Hasselle MD, Rose BS, Kochanski JD et al.. “Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix.” International journal of radiation oncology, biology, physics (2010). PMID: 20708346 ↗
L5OTHERCited in: Introduction and Epidemiology of Failure Patterns - [13]
Khalifa H, Ayaty M, Oreaba R et al.. “Neoadjuvant chemoradiation and surgical excision versus definitive radiotherapy for locally advanced cervix uteri carcinoma: in terms of early and late complications and locoregional recurrence.” Journal of the Egyptian National Cancer Institute (2025). PMID: 40481898 ↗
L4COHORTCited in: Introduction and Epidemiology of Failure Patterns - [14]
Yuan M, Zhang Y, Wang K et al.. “Case Report: Pelvic mass and massive ascites as the first symptom in cervical adenocarcinoma: report of two cases and literature review.” Frontiers in oncology (2023). PMID: 37637051 ↗
L4CASE_SERIESCited in: Introduction and Epidemiology of Failure Patterns - [15]
Zheng F, Yu H. “RASSF1A promoter methylation was associated with the development, progression and metastasis of cervical carcinoma: a meta-analysis with trial sequential analysis.” Archives of gynecology and obstetrics (2017). PMID: 29288321 ↗
L2SR_COHORTCited in: Biological Basis of Recurrence - [16]
Bonde J, Floore A, Ejegod D et al.. “Methylation markers FAM19A4 and miR124-2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter study.” International journal of cancer (2020). PMID: 32997803 ↗
L3COHORTCited in: Biological Basis of Recurrence - [17]
Huang Y, He Q, Xu K et al.. “A new marker based on risk stratification of human papillomavirus DNA and tumor size to predict survival of locally advanced cervical cancer.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2019). PMID: 30733276 ↗
L3COHORTCited in: Biological Basis of Recurrence - [18]
Gustinucci D, Ciccocioppo L, Coppola L et al.. “Multicentre Evaluation of Hepika Test Clinical Accuracy in Diagnosing HPV-Induced Cancer and Precancerous Lesions of the Uterine Cervix.” Diagnostics (Basel, Switzerland) (2021). PMID: 33808260 ↗
L3COHORTCited in: Biological Basis of Recurrence - [19]
Vink FJ, Meijer CJLM, Clifford GM et al.. “FAM19A4/miR124-2 methylation in invasive cervical cancer: A retrospective cross-sectional worldwide study.” International journal of cancer (2019). PMID: 31390052 ↗
L3CROSS_SECTIONALCited in: Biological Basis of Recurrence - [20]
Cañadas MP, Videla S, Darwich L et al.. “Human papillomavirus HPV-16, 18, 52 and 58 integration in cervical cells of HIV-1-infected women.” Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology (2010). PMID: 20427229 ↗
L3CROSS_SECTIONALCited in: Biological Basis of Recurrence - [21]
Álvarez-Paredes L, Santibañez M, Galiana A et al.. “Association of Human Papillomavirus Genotype 16 Viral Variant and Viral Load with Cervical High-grade Intraepithelial Lesions.” Cancer prevention research (Philadelphia, Pa.) (2019). PMID: 31208965 ↗
L3CROSS_SECTIONALCited in: Biological Basis of Recurrence - [22]
Abdoudaim MS, Bélec L, Ahmed MLCB et al.. “Human Papillomavirus Viral Load as Triage Biomarker for High-Grade Cervical Lesions and Invasive Cervical Carcinoma: A Cross-Sectional Study.” Health science reports (2025). PMID: 41255381 ↗
L3CROSS_SECTIONALCited in: Biological Basis of Recurrence - [23]
Carestiato FN, Afonso LA, Moysés N et al.. “An upward trend in DNA p16ink4a methylation pattern and high risk HPV infection according to the severity of the cervical lesion.” Revista do Instituto de Medicina Tropical de Sao Paulo (2013). PMID: 24037287 ↗
L3CROSS_SECTIONALCited in: Biological Basis of Recurrence - [24]
Hurjui RM, Hurjui IA, Buțureanu TA et al.. “HPV-Independent Cervical Cancer-A New Challenge of Modern Oncology.” International journal of molecular sciences (2025). PMID: 41155343 ↗
L5NARRATIVE_REVIEWCited in: Biological Basis of Recurrence - [25]
Reyna-Hernández MA, Alarcón-Romero LDC, Ortiz-Ortiz J et al.. “GLUT1, LDHA, and MCT4 Expression Is Deregulated in Cervical Cancer and Precursor Lesions.” The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society (2022). PMID: 35615882 ↗
L5OTHERCited in: Biological Basis of Recurrence - [26]
De Nola R, Loizzi V, Cicinelli E et al.. “Dynamic crosstalk within the tumor microenvironment of uterine cervical carcinoma: baseline network, iatrogenic alterations, and translational implications.” Critical reviews in oncology/hematology (2021). PMID: 33930531 ↗
L5NARRATIVE_REVIEWCited in: Biological Basis of Recurrence - [27]
Malinowski DP. “Multiple biomarkers in molecular oncology. I. Molecular diagnostics applications in cervical cancer detection.” Expert review of molecular diagnostics (2007). PMID: 17331061 ↗
L5NARRATIVE_REVIEWCited in: Biological Basis of Recurrence - [28]
Cintra RC, Céspedes AG, Conceição MPF et al.. “Computational insights into CRISP3 downregulation in cervical cancer and its cervical lineages pattern.” Precision clinical medicine (2024). PMID: 39139989 ↗
L5OTHERCited in: Biological Basis of Recurrence - [29]
Srivastava AJ, Contreras JA, Davis M et al.. “Early posttherapy clearance of human papillomavirus and treatment response in cervical carcinoma.” Cancer (2020). PMID: 32639597 ↗
L5OTHERCited in: Biological Basis of Recurrence - [30]
Banila C, Lorincz AT, Scibior-Bentkowska D et al.. “Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: A worldwide study.” International journal of cancer (2021). PMID: 34562270 ↗
L5OTHERCited in: Biological Basis of Recurrence - [31]
Fang B, Li Q, Wan Z et al.. “Exploring the Association Between Cervical Microbiota and HR-HPV Infection Based on 16S rRNA Gene and Metagenomic Sequencing.” Frontiers in cellular and infection microbiology (2022). PMID: 35800388 ↗
L5OTHERCited in: Biological Basis of Recurrence - [32]
Kurmyshkina OV, Dobrynin PV, Kovchur PI et al.. “Sequencing-based transcriptome analysis reveals diversification of immune response- and angiogenesis-related expression patterns of early-stage cervical carcinoma as compared with high-grade CIN.” Frontiers in immunology (2023). PMID: 37731500 ↗
L5OTHERCited in: Biological Basis of Recurrence - [33]
Liu W, Wang XJ, Cui YM et al.. “Clinicopathological and molecular characterization of HPV-associated cervical poorly cohesive carcinoma: a rare aggressive entity.” The journal of pathology. Clinical research (2026). PMID: 42289532 ↗
L5OTHERCited in: Biological Basis of Recurrence, Imaging Modalities for Detecting Recurrence - [34]
Girone C, Calati F, Lo Cigno I et al.. “The RIG-I agonist M8 triggers cell death and natural killer cell activation in human papillomavirus-associated cancer and potentiates cisplatin cytotoxicity.” Cancer immunology, immunotherapy : CII (2023). PMID: 37356050 ↗
L5OTHERCited in: Biological Basis of Recurrence - [35]
Stewart CJR, Koay MHE, Leslie C et al.. “Cervical carcinomas with a micropapillary component: a clinicopathological study of eight cases.” Histopathology (2017). PMID: 29034552 ↗
L5OTHERCited in: Anatomical Patterns of Failure: Local, Regional, and Distant - [36]
Chaudary N, Pintilie M, Hedley D et al.. “Hedgehog pathway signaling in cervical carcinoma and outcome after chemoradiation.” Cancer (2011). PMID: 22028038 ↗
L5OTHERCited in: Anatomical Patterns of Failure: Local, Regional, and Distant - [37]
Chen HH, Chou CY, Wu YH et al.. “Constitutive STAT5 activation correlates with better survival in cervical cancer patients treated with radiation therapy.” International journal of radiation oncology, biology, physics (2011). PMID: 21300446 ↗
L5OTHERCited in: Anatomical Patterns of Failure: Local, Regional, and Distant - [38]
Hong MK, Wang JH, Li MH et al.. “Topological Distribution of the Sex Hormone Receptor Expressions Highlights the Importance of Stromal ERα and Epithelial PR in Malignant Transformation of the Uterine Cervix.” International journal of molecular sciences (2025). PMID: 40362654 ↗
L5OTHERCited in: Anatomical Patterns of Failure: Local, Regional, and Distant - [39]
Toyoda S, Kita T, Sugiura A et al.. “Cervical adenocarcinoma with stromal micropapillary pattern.” Diagnostic cytopathology (2015). PMID: 26608235 ↗
L4CASE_SERIESCited in: Anatomical Patterns of Failure: Local, Regional, and Distant - [40]
Vasishta S, Varghese A, Ragheb A. “Patterns of failure in cervical carcinoma and outcome of salvage therapy: a retrospective study.” The Gulf journal of oncology (2007). PMID: 20084713 ↗
L4RETROSPECTIVE_COHORTCited in: Anatomical Patterns of Failure: Local, Regional, and Distant - [41]
Lawal IO, Ololade KO, Popoola GO et al.. “18F-FDG-PET/CT imaging of uterine cervical cancer recurrence in women with and without HIV infection.” The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of... (2019). PMID: 31089075 ↗
L5OTHERCited in: Anatomical Patterns of Failure: Local, Regional, and Distant - [42]
Lan LF, Chen YJ, Mo DC et al.. “Comparative effectiveness of immune checkpoint inhibitors in squamous vs. non-squamous cervical carcinoma: a systematic review and meta-analysis of randomized controlled trials.” Translational cancer research (2026). PMID: 42445390 ↗
L1SR_MA_RCTCited in: Imaging Modalities for Detecting Recurrence - [43]
Xiao C, Zeng S, Li L et al.. “Sentinel lymph node biopsy versus lymphadenectomy in early-stage cervical cancer: a meta-analysis of oncologic outcomes and surgical morbidity.” Frontiers in oncology (2026). PMID: 41858361 ↗
L1SR_MA_RCTCited in: Imaging Modalities for Detecting Recurrence, Outcomes and Survival After Failure - [44]
Verhoef L, Griffioen MS, Bleeker MCG et al.. “Triage Performance of FAM19A4/miR124-2 Methylation: 18-Month Follow-Up Results From a Prospective Observational Study Within the Dutch Primary HPV-Based Cervical Screening Program.” International journal of cancer (2026). PMID: 42373539 ↗
L4PROSPECTIVE_COHORTCited in: Imaging Modalities for Detecting Recurrence - [45]
van de Kam L, Siebers A, Bekkers R et al.. “Loss to follow-up in patients diagnosed with or treated for low- and high-grade squamous intraepithelial lesions: A comparison of general practitioner- and gynecologist-led surveillance.” Acta obstetricia et gynecologica Scandinavica (2026). PMID: 42480977 ↗
L3RETROSPECTIVE_COHORTCited in: Imaging Modalities for Detecting Recurrence - [46]
Yang K, Rong F, Chu F et al.. “Contrast-enhanced MRI improves the diagnostic performance for vaginal fornix invasion in cervical carcinoma.” Insights into imaging (2026). PMID: 42243469 ↗
L3RETROSPECTIVE_COHORTCited in: Imaging Modalities for Detecting Recurrence - [47]
Wolswinkel JT, Bekkers AHPA, Maurits JSF et al.. “Preoperative LVSI assessment in early-stage cervical cancer: Can it reliably guide lymph node management?” Gynecologic oncology (2026). PMID: 42224889 ↗
L3RETROSPECTIVE_COHORTCited in: Imaging Modalities for Detecting Recurrence - [48]
Adebisi TM, Oluwasola TAO, Ndikom CM et al.. “Feasibility of the effectiveness of a psychoeducational intervention on the physical and psychosexual functioning of women being treated for cervical cancer in a tertiary hospital in Southwest, Nigeria: a quasi-experimental study.” BMC cancer (2026). PMID: 42298499 ↗
L4NON_RANDOMIZED_TRIALCited in: Imaging Modalities for Detecting Recurrence - [49]
Li SY, Liu CY, Xie XY et al.. “Distribution analysis of gynecological carcinomas with concurrent second primary carcinomas.” Frontiers in oncology (2026). PMID: 42415866 ↗
L3COHORTCited in: Imaging Modalities for Detecting Recurrence - [50]
Darvishali MH, Nikkhah H, Rahavi H et al.. “HPV Genotypes and Survival Outcomes in Invasive Cervical Cancer: A Retrospective Molecular Analysis of FFPE Clinical Samples in an Iranian Cohort.” International journal of women's health (2026). PMID: 42022859 ↗
L3RETROSPECTIVE_COHORTCited in: Imaging Modalities for Detecting Recurrence - [51]
Huang Y, Shao J, Yin X et al.. “Comparative Analysis of Homologous Recombination Repair Status Across Gynecologic and Breast Cancers in Chinese Populations.” Current cancer drug targets (2026). PMID: 41935348 ↗
L3COHORTCited in: Imaging Modalities for Detecting Recurrence - [52]
Wang X, Liu Y, Li Y et al.. “The influence of postoperative risk factors on patient survival and lymph node metastasis in cervical squamous cell carcinoma.” BMC cancer (2026). PMID: 41872796 ↗
L3COHORTCited in: Imaging Modalities for Detecting Recurrence - [53]
Baral S, Silwal SR, Bhattarai N et al.. “Evaluation of Quality Indicators for Radiation Therapy of Cervical Cancer: Experience From a Tertiary Cancer Center in Nepal.” JCO global oncology (2026). PMID: 41843834 ↗
L3COHORTCited in: Imaging Modalities for Detecting Recurrence - [54]
Zhao J, Wang L, Shao N et al.. “RRM2/GCH1 signaling decreased cisplatin sensitivity in cervical cancer by modulating the ferroptosis process.” Histology and histopathology (2026). PMID: 41789593 ↗
L3CASE_CONTROLCited in: Imaging Modalities for Detecting Recurrence - [55]
Hamod A, Mihaela O, Grigore M et al.. “Cervicovaginal Microbiome Signatures Across Cervical Disease States: A Prospective Cross-Sectional Analysis.” Diagnostics (Basel, Switzerland) (2026). PMID: 41828029 ↗
L3CROSS_SECTIONALCited in: Imaging Modalities for Detecting Recurrence - [56]
Ryszkiewicz P, Baranowska-Kuczko M, Malinowska B et al.. “Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.” Pharmacological reports : PR (2026). PMID: 42484993 ↗
L5NARRATIVE_REVIEWCited in: Imaging Modalities for Detecting Recurrence - [57]
Rath N, Neis K, Holleczek B. “Analysis of Age, Period and Cohort Trends in Cervical In Situ and Invasive Carcinomas for Assessing the Utility of Screening Approaches-Results From the Saarland Cancer Registry.” Cancer medicine (2026). PMID: 42482636 ↗
L5OTHERCited in: Imaging Modalities for Detecting Recurrence - [58]
Gu NH, Luo LJ, Yang NP et al.. “Correlations between TSC Expression and Menorrhagia in Adenomyosis Patients.” Reproductive sciences (Thousand Oaks, Calif.) (2026). PMID: 42481897 ↗
L5OTHERCited in: Imaging Modalities for Detecting Recurrence - [59]
Zhang Y, Zou H, Deng S et al.. “Impact of WFDC2 on the biological functions of cervical cancer cells and the regulation of the ERK/NF‑κB signaling pathway.” Oncology reports (2026). PMID: 42396650 ↗
L5OTHERCited in: Imaging Modalities for Detecting Recurrence - [60]
Massenberg A, Homsi Y, Schneider CN et al.. “A rapid transfer of virions coated with heparan sulfate from the ECM to CD151 defines an early step in the human papillomavirus infection cascade.” eLife (2026). PMID: 42299855 ↗
L5OTHERCited in: Imaging Modalities for Detecting Recurrence - [61]
Rose PG, Java J, Whitney CW et al.. “Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732170 ↗
L1RCTCited in: Impact of Primary Treatment Modality on Failure Patterns, Outcomes and Survival After Failure - [62]
Sardain H, Lavoue V, Redpath M et al.. “Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic review.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2015). PMID: 25922209 ↗
L2SR_COHORTCited in: Impact of Primary Treatment Modality on Failure Patterns - [63]
Zhu J, Zhang Z, Bian D et al.. “Weekly versus triweekly cisplatin-based concurrent chemoradiotherapy in the treatment of locally advanced cervical carcinoma: An updated meta-analysis based on randomized controlled trials.” Medicine (2020). PMID: 31895831 ↗
L1SR_MA_RCTCited in: Impact of Primary Treatment Modality on Failure Patterns - [64]
Gangopadhyay A, Saha S. “Pelvic side wall recurrence in locally advanced cervical carcinoma treated with definitive chemoradiation-clinical impact of pelvic wall dose.” The British journal of radiology (2019). PMID: 31322915 ↗
L1RCTCited in: Impact of Primary Treatment Modality on Failure Patterns, Future Directions and Emerging Therapies - [65]
Li D, Wen E, Zhang Y et al.. “Preliminary report of a single-channel applicator in high dose rate afterloading brachytherapy for cervical cancer.” Cancer science (2018). PMID: 30353607 ↗
L4RCTCited in: Impact of Primary Treatment Modality on Failure Patterns - [66]
Landoni F, Colombo A, Milani R et al.. “Randomized study between radical surgery and radiotherapy for the treatment of stage IB-IIA cervical cancer: 20-year update.” Journal of gynecologic oncology (2017). PMID: 28382797 ↗
L1RCTCited in: Impact of Primary Treatment Modality on Failure Patterns, Future Directions and Emerging Therapies - [67]
Liu R, Wang X, Tian JH et al.. “High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer.” The Cochrane database of systematic reviews (2014). PMID: 25300170 ↗
L1SR_MA_RCTCited in: Impact of Primary Treatment Modality on Failure Patterns - [68]
Wang K, Qu A, Deng X et al.. “Efficacy and safety of 3-dimensional printing noncoplanar template (3D-PNCT)-assisted high-dose-rate interstitial brachytherapy (HDR-ISBT) for reirradiation of recurrent cervical cancer: a prospective cohort.” Journal of gynecologic oncology (2024). PMID: 38991947 ↗
L4PROSPECTIVE_COHORTCited in: Impact of Primary Treatment Modality on Failure Patterns, Management Strategies for Recurrent Cervical Cancer, Outcomes and Survival After Failure - [69]
Vercellino GF, Piek JM, Schneider A et al.. “Laparoscopic lymph node dissection should be performed before fertility preserving treatment of patients with cervical cancer.” Gynecologic oncology (2012). PMID: 22704949 ↗
L4PROSPECTIVE_COHORTCited in: Impact of Primary Treatment Modality on Failure Patterns - [70]
Gandhi AK, Rastogi M, Khurana R et al.. “Five-Year Outcomes of Moderately Hypofractionated Whole Pelvic Radiation Therapy with Concurrent Chemotherapy and Image Guided High Dose Rate Brachytherapy for Locally Advanced Cervical Carcinoma.” International journal of radiation oncology, biology, physics (2025). PMID: 41319720 ↗
L2NON_RANDOMIZED_TRIALCited in: Impact of Primary Treatment Modality on Failure Patterns, Future Directions and Emerging Therapies - [71]
Dávila Fajardo R, van Os R, Buist MR et al.. “Post-operative radiotherapy in patients with early stage cervical cancer.” Gynecologic oncology (2014). PMID: 24784874 ↗
L2NON_RANDOMIZED_TRIALCited in: Impact of Primary Treatment Modality on Failure Patterns - [72]
Legge F, Bizzarri N, Gallotta V et al.. “Locally advanced cervical carcinoma patients treated with chemoradiation followed by radical surgery: clinical response and oncological outcomes according to histotype after propensity score analysis.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2022). PMID: 35450757 ↗
L3COHORTCited in: Impact of Primary Treatment Modality on Failure Patterns - [73]
Engineer R, Chopra S, Shukla R et al.. “Computed Tomography-Based Interstitial Brachytherapy for Recurrent Cervical Carcinoma in the Vaginal Apex.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2021). PMID: 34716084 ↗
L4COHORTCited in: Impact of Primary Treatment Modality on Failure Patterns - [74]
Tomalczyk A, Tomasik B, Fijuth J et al.. “Assessment of cervical vascularization density in patients with locally advanced squamous cell cervical carcinoma evaluated in colour Doppler and power Doppler functions.” Archives of gynecology and obstetrics (2021). PMID: 34586470 ↗
L3COHORTCited in: Impact of Primary Treatment Modality on Failure Patterns - [75]
Li C, Li X, You J et al.. “Impact of radiation source activity on short- and long-term outcomes of cervical carcinoma patients treated with high-dose-rate brachytherapy: A retrospective cohort study.” Gynecologic oncology (2020). PMID: 32933759 ↗
L3RETROSPECTIVE_COHORTCited in: Impact of Primary Treatment Modality on Failure Patterns - [76]
Kozak MM, Koenig JL, von Eyben R et al.. “Less Than Whole Uterus Irradiation for Locally Advanced Cervical Cancer Maintains Locoregional Control and Decreases Radiation Dose to Bowel.” Practical radiation oncology (2018). PMID: 30395974 ↗
L4COHORTCited in: Impact of Primary Treatment Modality on Failure Patterns - [77]
Elmajjaoui S, Ismaili N, El Kacemi H et al.. “Epidemiology and outcome of cervical cancer in national institute of Morocco.” BMC women's health (2016). PMID: 27618814 ↗
L3COHORTCited in: Impact of Primary Treatment Modality on Failure Patterns, Outcomes and Survival After Failure - [78]
Ou X, You J, Liang B et al.. “Prognostic Factors Analysis of Metastatic Recurrence in Cervical Carcinoma Patients Treated with Definitive Radiotherapy: A Retrospective Study Using Mixture Cure Model.” Cancers (2023). PMID: 37296875 ↗
L3COHORTCited in: Prognostic Factors and Risk Stratification for Recurrence - [79]
Akilli H, Tohma YA, Bulut AN et al.. “Comparison of no adjuvant treatment and radiotherapy in early-stage cervical carcinoma with intermediate risk factors.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2020). PMID: 32246761 ↗
L3RETROSPECTIVE_COHORTCited in: Prognostic Factors and Risk Stratification for Recurrence - [80]
Bizzarri N, Pedone Anchora L, Kucukmetin A et al.. “Protective Role of Conization Before Radical Hysterectomy in Early-Stage Cervical Cancer: A Propensity-Score Matching Study.” Annals of surgical oncology (2021). PMID: 33620615 ↗
L4RETROSPECTIVE_COHORTCited in: Prognostic Factors and Risk Stratification for Recurrence - [81]
Kodaira T, Fuwa N, Nakanishi T et al.. “Prospective study of alternating chemoradiotherapy consisting of extended-field dynamic conformational radiotherapy and systemic chemotherapy using 5-FU and nedaplatin for patients in high-risk group with cervical carcinoma.” International journal of radiation oncology, biology, physics (2008). PMID: 18513885 ↗
L4PHASE_1_TRIALCited in: Prognostic Factors and Risk Stratification for Recurrence - [82]
Purut YE, Giray B, Akis S et al.. “Effect of Human Papillomavirus Subtype on the Rate of Positive Surgical Margin After Cervical Conization.” International journal of surgical pathology (2022). PMID: 36514291 ↗
L3COHORTCited in: Prognostic Factors and Risk Stratification for Recurrence - [83]
Na J, Li Y, Lu Q et al.. “Investigating the impact of persistent HPV infection on recurrence of lesions post-surgery for early-stage cervical cancer and related influencing factors.” Frontiers in oncology (2025). PMID: 39968075 ↗
L4COHORTCited in: Prognostic Factors and Risk Stratification for Recurrence - [84]
Tantari M, Bogliolo S, Morotti M et al.. “Lymph Node Involvement in Early-Stage Cervical Cancer: Is Lymphangiogenesis a Risk Factor? Results from the MICROCOL Study.” Cancers (2022). PMID: 35008376 ↗
L5OTHERCited in: Prognostic Factors and Risk Stratification for Recurrence - [85]
Pol FJ, Zusterzeel PL, van Ham MA et al.. “Satellite lymphovascular space invasion: An independent risk factor in early stage cervical cancer.” Gynecologic oncology (2015). PMID: 26126782 ↗
L5OTHERCited in: Prognostic Factors and Risk Stratification for Recurrence - [86]
Gao P, Zhou GY, Yin G et al.. “Lymphatic vessel density as a prognostic indicator for patients with stage I cervical carcinoma.” Human pathology (2006). PMID: 16733213 ↗
L5OTHERCited in: Prognostic Factors and Risk Stratification for Recurrence - [87]
Case AS, Rocconi RP, Straughn JM et al.. “Cervical intraepithelial neoplasia in adolescent women: incidence and treatment outcomes.” Obstetrics and gynecology (2006). PMID: 17138768 ↗
L5OTHERCited in: Prognostic Factors and Risk Stratification for Recurrence - [88]
Ghaemmaghami F, Saleh-Gargari S, Sahebdel B et al.. “Risk factors and clinical aspects of recurrent invasive cervical carcinoma.” Journal of obstetrics and gynaecology of India (2012). PMID: 24293846 ↗
L3COHORTCited in: Prognostic Factors and Risk Stratification for Recurrence - [89]
Sharma DN, Rath GK, Kumar R et al.. “Positron emission tomography scan for predicting clinical outcome of patients with recurrent cervical carcinoma following radiation therapy.” Journal of cancer research and therapeutics (2012). PMID: 22531509 ↗
L2NON_RANDOMIZED_TRIALCited in: Management Strategies for Recurrent Cervical Cancer, Future Directions and Emerging Therapies - [90]
Lee YS, Kim YS, Kim JH et al.. “Feasibility and outcome of concurrent chemoradiotherapy for recurrent cervical carcinoma after initial surgery.” Tumori (2010). PMID: 20968134 ↗
L4COHORTCited in: Management Strategies for Recurrent Cervical Cancer - [91]
Grieco V, Fiorito D, Giorgianni G et al.. “HPV Vaccine: An Effective but Underutilized Prevention Tool.” International journal of environmental research and public health (2025). PMID: 41464477 ↗
L3COHORTCited in: Management Strategies for Recurrent Cervical Cancer - [92]
Murakami N, Shima S, Okuma K et al.. “Artificial ascites for organs at risk sparing in intrapelvic brachytherapy: a case report of recurrent uterine cervical carcinoma adjacent to the bowel.” BJR case reports (2018). PMID: 31131133 ↗
L4CASE_SERIESCited in: Management Strategies for Recurrent Cervical Cancer - [93]
Petrelli F, De Stefani A, Raspagliesi F et al.. “Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: a systematic review and meta-analysis.” Gynecologic oncology (2014). PMID: 24793000 ↗
L1SR_MA_RCTCited in: Outcomes and Survival After Failure - [94]
Fatima E, Abdul Rehman K, Ur Rehman O et al.. “Efficacy and safety of adjuvant chemotherapy for locally advanced cervical carcinoma: an updated Systematic review and meta-analysis.” Journal of chemotherapy (Florence, Italy) (2026). PMID: 41518610 ↗
L1SR_MA_RCTCited in: Outcomes and Survival After Failure - [95]
Rotman M, Sedlis A, Piedmonte MR et al.. “A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study.” International journal of radiation oncology, biology, physics (2006). PMID: 16427212 ↗
L1RCTCited in: Outcomes and Survival After Failure, Future Directions and Emerging Therapies - [96]
Schwarz JK, Siegel BA, Dehdashti F et al.. “Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma.” JAMA (2007). PMID: 18029833 ↗
L2PROSPECTIVE_COHORTCited in: Outcomes and Survival After Failure - [97]
Tinker AV, Fiorino L, O'Dwyer H et al.. “Bevacizumab in Metastatic, Recurrent, or Persistent Cervical Cancer: The BC Cancer Experience.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2018). PMID: 30247250 ↗
L2NON_RANDOMIZED_TRIALCited in: Outcomes and Survival After Failure - [98]
Sharma DN, Rath GK, Julka PK et al.. “Role of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligible or refractory to systemic chemotherapy: first study from Asia.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2013). PMID: 23466569 ↗
L2NON_RANDOMIZED_TRIALCited in: Outcomes and Survival After Failure, Future Directions and Emerging Therapies - [99]
Choi CH, Lee JW, Kim TJ et al.. “Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results.” International journal of radiation oncology, biology, physics (2007). PMID: 17379437 ↗
L4NON_RANDOMIZED_TRIALCited in: Outcomes and Survival After Failure, Future Directions and Emerging Therapies - [100]
Chan JK, Deng W, Higgins RV et al.. “A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study.” Gynecologic oncology (2017). PMID: 28728751 ↗
L2NON_RANDOMIZED_TRIALCited in: Outcomes and Survival After Failure, Future Directions and Emerging Therapies - [101]
Salvo G, Flores Legarreta A, Ramalingam P et al.. “Clinicopathologic characteristics, oncologic outcomes, and prognostic factors in neuroendocrine cervical carcinoma: a Neuroendocrine Cervical Tumor Registry study.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2023). PMID: 37567596 ↗
L3COHORTCited in: Outcomes and Survival After Failure - [102]
Leitao MM, Zhou QC, Brandt B et al.. “The MEMORY Study: MulticentEr study of Minimally invasive surgery versus Open Radical hYsterectomy in the management of early-stage cervical cancer: Survival outcomes.” Gynecologic oncology (2022). PMID: 35879128 ↗
L3RETROSPECTIVE_COHORTCited in: Outcomes and Survival After Failure - [103]
Dhesi SS, Frood R, Swift S et al.. “Prediction of Patient Outcomes in Locally Advanced Cervical Carcinoma Following Chemoradiotherapy-Comparative Effectiveness of Magnetic Resonance Imaging and 2-Deoxy-2-[18F]fluoro-D-glucose Imaging.” Cancers (2024). PMID: 38339229 ↗
L4COHORTCited in: Outcomes and Survival After Failure - [104]
Liu Y, Jiang P, Zhang H et al.. “Safety and efficacy of 3D-printed templates assisted CT-guided radioactive iodine-125 seed implantation for the treatment of recurrent cervical carcinoma after external beam radiotherapy.” Journal of gynecologic oncology (2020). PMID: 33300313 ↗
L4COHORTCited in: Outcomes and Survival After Failure - [105]
Nishio S, Katsumata N, Matsumoto K et al.. “Analysis of the clinicopathological prognosis of stage IVb cervical carcinoma.” Oncology reports (2008). PMID: 18202800 ↗
L4COHORTCited in: Outcomes and Survival After Failure - [106]
Yoon HI, Cha J, Keum KC et al.. “Treatment outcomes of extended-field radiation therapy and the effect of concurrent chemotherapy on uterine cervical cancer with para-aortic lymph node metastasis.” Radiation oncology (London, England) (2015). PMID: 25582425 ↗
L4COHORTCited in: Outcomes and Survival After Failure - [107]
Cheng X, Cai SM, Li ZT et al.. “Concurrent chemotherapy and adjuvant extended field irradiation after radical surgery for cervical cancer patients with lymph node metastases.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2007). PMID: 17944922 ↗
L4COHORTCited in: Outcomes and Survival After Failure - [108]
Zanagnolo V, Minig L, Rollo D et al.. “Clinical and Oncologic Outcomes of Robotic Versus Abdominal Radical Hysterectomy for Women With Cervical Cancer: Experience at a Referral Cancer Center.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2016). PMID: 26825827 ↗
L3COHORTCited in: Outcomes and Survival After Failure - [109]
Pötter R, Haie-Meder C, Van Limbergen E et al.. “Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2006). PMID: 16403584 ↗
L1GUIDELINECited in: Guidelines, Consensus Statements, and Clinical Pathways - [110]
Beckmann MW, Mallmann P. “Interdisciplinary S2k guideline on the diagnosis and treatment of cervical carcinoma.” Journal of cancer research and clinical oncology (2009). PMID: 19288271 ↗
L1GUIDELINECited in: Guidelines, Consensus Statements, and Clinical Pathways - [111]
Morice P, Narducci F, Mathevet P et al.. “French recommendations on the management of invasive cervical cancer during pregnancy.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2009). PMID: 19955951 ↗
L1GUIDELINECited in: Guidelines, Consensus Statements, and Clinical Pathways - [112]
Wolfson AH, Varia MA, Moore D et al.. “ACR Appropriateness Criteria® role of adjuvant therapy in the management of early stage cervical cancer.” Gynecologic oncology (2011). PMID: 22155418 ↗
L1GUIDELINECited in: Guidelines, Consensus Statements, and Clinical Pathways - [113]
Lee LJ, Das IJ, Higgins SA et al.. “American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III: low-dose-rate and pulsed-dose-rate brachytherapy.” Brachytherapy (2012). PMID: 22265438 ↗
L1GUIDELINECited in: Guidelines, Consensus Statements, and Clinical Pathways - [114]
Viswanathan AN, Thomadsen B. “American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles.” Brachytherapy (2012). PMID: 22265436 ↗
L1GUIDELINECited in: Guidelines, Consensus Statements, and Clinical Pathways - [115]
Shakespeare TP, Lim KH, Lee KM et al.. “Phase II study of the American Brachytherapy Society guidelines for the use of high-dose rate brachytherapy in the treatment of cervical carcinoma: is 45-50.4 Gy radiochemotherapy plus 31.8 Gy in six fractions high-dose rate brachytherapy tolerable?” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2006). PMID: 16445645 ↗
L2NON_RANDOMIZED_TRIALCited in: Guidelines, Consensus Statements, and Clinical Pathways - [116]
Garritsen FM, Verheijen RHM, Gerestein CG et al.. “Is there an increased risk of cervical neoplasia in atopic dermatitis patients treated with oral immunosuppressive drugs?” Journal of the European Academy of Dermatology and Venereology : JEADV (2017). PMID: 28925576 ↗
L3RETROSPECTIVE_COHORTCited in: Guidelines, Consensus Statements, and Clinical Pathways - [117]
Menon SS, Rossi R, Harebottle R et al.. “Distribution of human papillomaviruses and bacterial vaginosis in HIV positive women with abnormal cytology in Mombasa, Kenya.” Infectious agents and cancer (2016). PMID: 27053945 ↗
L4COHORTCited in: Guidelines, Consensus Statements, and Clinical Pathways - [118]
Francoeur AA, Liao CI, Caesar MA et al.. “The increasing incidence of stage IV cervical cancer in the USA: what factors are related?” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2022). PMID: 35981903 ↗
L5OTHERCited in: Guidelines, Consensus Statements, and Clinical Pathways - [119]
Stuebs FA, Beckmann MW, Fehm T et al.. “Implementation and update of guideline-derived quality indicators for cervical cancer in gynecological cancer centers certified by the German Cancer Society (DKG).” Journal of cancer research and clinical oncology (2023). PMID: 37452203 ↗
L5OTHERCited in: Guidelines, Consensus Statements, and Clinical Pathways - [120]
Qin Y, Guan P, Li D et al.. “Successful inguinal interstitial brachytherapy in metastatic cervical carcinoma: a case report.” Frontiers in oncology (2024). PMID: 38288097 ↗
L4CASE_SERIESCited in: Guidelines, Consensus Statements, and Clinical Pathways - [121]
Telner DE, Jakubovicz D. “Approach to diagnosis and management of abnormal uterine bleeding.” Canadian family physician Medecin de famille canadien (2007). PMID: 17872610 ↗
L4CASE_SERIESCited in: Guidelines, Consensus Statements, and Clinical Pathways - [122]
Tewari KS, Sill MW, Penson RT et al.. “Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).” Lancet (London, England) (2017). PMID: 28756902 ↗
L1RCTCited in: Future Directions and Emerging Therapies - [123]
Mathevet P, Lécuru F, Uzan C et al.. “Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2).” European journal of cancer (Oxford, England : 1990) (2021). PMID: 33773275 ↗
L1RCTCited in: Future Directions and Emerging Therapies - [124]
Chapman JA, Costantino JP, Dong B et al.. “Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.” Breast cancer research and treatment (2015). PMID: 26276354 ↗
L1RCTCited in: Future Directions and Emerging Therapies - [125]
Geara FB, Shamseddine A, Khalil A et al.. “A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer.” Radiation oncology (London, England) (2010). PMID: 20863389 ↗
L2RCT_PHASE2Cited in: Future Directions and Emerging Therapies - [126]
Park ST, Song MJ, Park JS et al.. “Incidence and clinicopathologic behavior of uterine cervical carcinoma in renal transplant recipients.” World journal of surgical oncology (2011). PMID: 21752252 ↗
L2NON_RANDOMIZED_TRIALCited in: Future Directions and Emerging Therapies - [127]
Singh RK, Maulik S, Mitra S et al.. “Human papillomavirus prevalence in postradiotherapy uterine cervical carcinoma patients: correlation with recurrence of the disease.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2006). PMID: 16803484 ↗
L2NON_RANDOMIZED_TRIALCited in: Future Directions and Emerging Therapies - [128]
Zanaboni F, Grijuela B, Giudici S et al.. “Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study.” European journal of cancer (Oxford, England : 1990) (2012). PMID: 23151423 ↗
L2NON_RANDOMIZED_TRIALCited in: Future Directions and Emerging Therapies - [129]
Choi CH, Kim TJ, Lee SJ et al.. “Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2006). PMID: 16803500 ↗
L2NON_RANDOMIZED_TRIALCited in: Future Directions and Emerging Therapies - [130]
Höckel M. “Do we need a new classification for radical hysterectomy? Insights in surgical anatomy and local tumor spread from human embryology.” Gynecologic oncology (2007). PMID: 17727931 ↗
L2NON_RANDOMIZED_TRIALCited in: Future Directions and Emerging Therapies - [131]
Eitan R, Levavi H, Peled Y et al.. “Should simple hysterectomy be added after chemo-radiation for stage IB2 and bulky IIA cervical carcinoma?” The Australian & New Zealand journal of obstetrics & gynaecology (2010). PMID: 20618249 ↗
L2NON_RANDOMIZED_TRIALCited in: Future Directions and Emerging Therapies - [132]
Miglietta L, Franzone P, Centurioni MG et al.. “A phase II trial with cisplatin-paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or recurrent cervical cancer.” Oncology (2006). PMID: 16439862 ↗
L2NON_RANDOMIZED_TRIALCited in: Future Directions and Emerging Therapies - [133]
Badakh DK, Grover AH. “Reirradiation with high-dose-rate remote afterloading brachytherapy implant in patients with locally recurrent or residual cervical carcinoma.” Journal of cancer research and therapeutics (2009). PMID: 19293485 ↗
L2NON_RANDOMIZED_TRIALCited in: Future Directions and Emerging Therapies